CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Zevalin plus BEAMdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00138086
NCT00138086Phase 2Completed
CompareCT.gov

Targeted Intensification by a New Preparative Regimen for Patients With Low-Grade B-Cell Lymphoma Utilizing Standard-Dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-Dose Beam Followed by Autologous Stem Cell Transplantation (ASCT)

Lymphoma Study Association·interventional·Posted Aug 30, 2005·Updated Sep 8, 2006

In Brief

A Phase 2 clinical trial evaluating Zevalin plus BEAM for B-Cell Lymphoma. Completed, across 9 sites in 3 countries.

Detailed Summary

The objective of this study is to evaluate the efficacy and the safety of Zevalin-BEAM preparative regimen before autologous stem cell transplantation (ASCT) as measured by the event free survival (EFS). The goal is to obtain a 15% increase of EFS at 2 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-Cell Lymphoma
CountriesBelgium, France, Switzerland
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 30, 2005
Enrollment StartMar 1, 2005
Study CompletionMar 1, 2009
TodayJul 2, 2026
Posted 20.8 years ago

Interventions

Zevalin plus BEAMdrug